Cefditoren
Systematic (IUPAC) name
(7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((Z)-2-(4-methylthiazol-5-yl)vinyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Spectracef
AHFS/Drugs.com
MedlinePlus
Identifiers
CAS Registry Number  N
ATC code J01
PubChem CID:
DrugBank  YesY
ChemSpider  YesY
UNII  YesY
KEGG  N
ChEBI  YesY
ChEMBL  N
Chemical data
Formula N6O5S3
Molecular mass 506.58 g/mol
 N   

Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Vansen Pharma Inc.

Cefditoren is also marketed under the name Meiact by Meiji Seika Pharma Co., Ltd.[1]

Spectrum of bacterial susceptibility

Cefditoren has a broad spectrum of activity and has been used to treat bacterial infections of the skin and respiratory tract, including bronchitis, pneumonia, and tonsillitis. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Haemophilus influenzae: ≥0.063 - 0.25 μg/ml
  • Staphylcoccus aureus: 0.25 - >128 μg/ml (includes MRSA)
  • Streptococcus pyogenes: ≤0.004 - 2 μg/ml[2]

Cefditoren is a broad-spectrum antibiotic against Gram-negative and Gram-positive bacteria, but does not have antibacterial activity against Pseudomonas aeruginosa.[3]

Clinical use

Indications

Cefditoren is used to treat uncomplicated skin and skin structure infections, community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis, and tonsillitis.

Formulations

Cefditoren is available as 200- and 400-mg tablets. It can be formulated as the prodrug cefditoren pivoxil.

Chemical structure of cefditoren pivoxil

References

  1. ^ Meiact Full Description
  2. ^ http://www.toku-e.com/Assets/MIC/Cefditoren%20sodium.pdf
  3. ^

External links

  • Manufacturer's Product website
  • Manufacturer's prescribing information for Spectracef